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Introduction
Gout is strongly associated with comorbidities, including obe-
sity, metabolic syndrome, type II diabetes, hyperlipidemia, 
hypertension, chronic kidney disease (CKD), and coronary 
artery disease.1-3 Comorbidities frequently restrict conventional 
treatment options (ie, nonsteroidal anti-inflammatory drugs 
[NSAIDs], colchicine, corticosteroids) for gout flares.3 Acute 
gout flares are mediated by NLRP3 inflammasome activation 
with consequent interleukin-1β (IL-1β) release.4 Interleukin-1 
(IL-1) antagonism, using the IL-1β-specific antibody canaki-
numab, is approved in Europe for gout flare. Off-label prescrip-
tion of the soluble IL-1 receptor antagonist anakinra has been 
reported effective in case series,5-10 including in hospitalized 
inpatients.11-14 Anakinra was noninferior to conventional 
approved therapies for acute gouty arthritis in a recent controlled 
trial.15 To add insight, for clinical medicine, on baseline charac-
teristics, and long-term mortality risk, in patients who ultimately 
received ⩾1 rheumatologist-prescribed anakinra courses for 
acute gout, we conducted a randomized, case-control study.
Methods
We focused on a Veterans Affairs (VA) hospital group rheu-
matology practice, where anakinra pre-authorization was 
needed, with prescriptions limited to stringent managed care 
principles, for contraindication or failure of conventional acute 
gout therapies. VA San Diego Healthcare System Human 
Subjects Committee ethics board approved (#130245) the 
study of electronic records of 1451 patients fulfilling 2015 
ACR/EULAR gout criteria,16 and seen by rheumatology 
between January 1, 2003 and January 27, 2015. All reviewed 
material was fully de-identified, retrospective information. A 
total of 13 patients received anakinra for gout flare, with 
demographics shown in Figure 1.
In retrospective case-control analyses, 4 age- and sex-matched 
controls were chosen (by randomization) for each patient who 
received anakinra (Figure 1). Control selection used search crite-
ria in health records: gout diagnosis by International Classification 
of Diseases—Ninth Revision (ICD-9) coding, ⩾1 visit to VA 
rheumatology clinic or inpatient rheumatology consultation, and 
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no recorded anakinra use. The first recorded rheumatology clini-
cal encounter during the study period was analyzed. Gout flares 
were defined by validated criteria.17 Factor analysis of mixed data 
(FAMD), to explore similarities between all variables (quantita-
tive and qualitative) for all individuals, was performed using 
FactoMineR (version 1.39) within the R environment (version 
3.4.3).18,19 Relative risk (RR) was calculated as described by 
Altman.20
Results
At initial rheumatology visit, patients ultimately receiving anak-
inra more frequently had palpable tophi and higher serum urate 
(Table 1). There were no significant differences in the mean 
Figure 1. Flow diagram for patient selection and study design. VA 
indicates Veterans Affairs.
Table 1. Overview of demographics of patient populations and clinical profiles.
ALL PATIENTS (N = 65) ANAkINRA 
gROUP (N = 13)
CONTROL gROUP (AgE AND 
SEx MATCHED) (N = 52)
P VALUEa P VALUEb
Clinical profile  
 Palpable tophus detected, n (%) 10/13 (77) 16/52 (31) .003 .03
 Serum uric acid (mg/dL) 10.66 7.65 <.001 .02
 Mean number of comorbidities 3.92 3.18 .112
CI = –0.18 to 1.67
.31
 Diabetes, n (%) 7 (54) 19 (37) .35 .58
 Hypertension, n (%) 12 (93) 39 (75) .27 .49
 CkD—stage 3 or greater, n (%) 8 (62) 13 (25) .02 .09
 CHF, n (%) 4 (31) 10 (20) .45 .71
 Obesity, n (%) 8 (62) 33 (64) 1.00 1.00
Ethnicity, n (%)
 Black 1 (7) 8 (15) .67 .87
 East Asian 7 (54) 16 (31) .04 .15
 White 5 (39) 29 (56) 1.00 1.00
 Hispanic 0 (0) 4 (7) .58 .84
Medications at baseline, n (%)
 Urate-lowering therapy 7 (54) 17 (33) .21 .45
 NSAIDs 6 (47) 26 (50) 1.00 1.00
 Steroids 3 (23) 10 (20) .72 .87
 Colchicine 8 (62) 17 (33) .11 .31
 Metformin 2 (16) 6 (12) .66 .87
 Insulin 3 (23) 5 (10) .20 .45
 Loop diuretics 4 (31) 8 (16) .24 .47
 Statins 9 (70) 15 (29) .01 .08
 Thiazides 1 (8) 3 (6) 1.00 1.00
Abbreviations: CHF, congestive heart failure; CI, confidence interval; CkD, chronic kidney disease; NSAIDs, nonsteroidal anti-inflammatory drugs.
Bold font for individual P values indicates statistical significance.
aUncorrected P values calculated using unpaired t tests.
bP values corrected by the Benjamini-Hochberg procedure for multiple comparisons.
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number of selected comorbidities (mean of 3.9 in anakinra, 3.1 
in controls, P = .11, confidence interval [CI] = –0.18 to 1.67; 
Table 1), but ultimate all-cause mortality was greater in those 
who had received anakinra for acute flare ([6/13] vs controls 
[7/52], RR = 3.43, 95% CI = 1.39-8.48, P = .0076). East Asian 
patients were more likely to be treated with anakinra (Table 1).
Most patients had several anakinra courses for gout flares 
and responded and tolerated anakinra well (not shown). 
Although the cause of death for several patients in the anakinra 
treatment group remains unknown, congestive heart failure 
(CHF) decompensation as precipitant was confirmed in 2 and 
septic shock (approximately 12 months from the last anakinra 
dose) in 1 who had received the most courses of anakinra 
(Table 2). By comparison, of 52 controls, 7 died during the 
study period (Table 2). Two patients were found dead at home 
and 3 died from complications of metastatic neoplasms. One 
with end-stage renal disease had a cardiac arrest during dialysis 
and 1 with neurogenic bladder died from renal failure, after 
declining dialysis.
Factor analysis of mixed data was applied to the qualitative 
variables shown in Figure 2, as well as estimated glomerular 
filtration rate (eGFR), total number of comorbidities per indi-
vidual, and uric acid level (quantitative variables), for all indi-
viduals. Here, 35.51% of total variance of the data is represented 
within the first 2 dimensions. Eventual anakinra use was most 
strongly associated with baseline palpable tophus, and statin or 
urate-lowering therapy (ULT), which was exclusively allopuri-
nol. There was distinct clustering, with either insulin or loop 
Table 2. Details related to anakinra use and ultimate mortality in the anakinra treatment group.
PATIENT NUMBER OF 
COURSES OF 
ANAkINRA
RESPONSE 
TO ANAkINRA 
(DETERMINED By 
TREATINg PHySICIAN)
SIDE EFFECTS RE-FLARE IN 21 DAyS OR 
LESS
CAUSE OF DEATH, IF 
APPLICABLE
1 3 courses (100 mg/
day × 5 days)
Excellent (complete and 
rapid response)
None 1 repeat flare in 3 days 
after the first course. 1 
repeat flare at 14 days 
after the second course
N/A
2 1 course 
(100 mg/d × 3 days)
Substantial None Repeat flare at 7 days 
post cessation
N/A
3 8 courses 
(100 mg/d × 3-5 days)
Excellent Nonspecific 
malaise, dizziness
Minor flares at different 
sites within 14 days post 
cessation for the last 3 
flares requiring anakinra
Clostridium difficile 
infection, health-
care-associated 
pneumonia, renal 
failure
4 1 course 
(100 mg/d × 3 days)
Excellent None Re-flare in 14 days post 
cessation
N/A
5 1 course 
(100 mg/d × 3 days)
Lost to follow-up Lost to follow-up Lost to follow-up N/A
6 1 course 
(100 mg/d × 21 days)
Excellent Injection site 
reaction
Re-flare in 14 days post 
cessation
N/A
7 1 course 
(100 mg/d × 5 days)
Substantial None Flare still ongoing (but 
improved) at 21 days post 
anakinra
N/A
8 1 course 
(100 mg/d × 3 days)
Excellent None Lost to follow-up N/A
9 1 course 
(100 mg/d × 3 days)
Substantial None Re-flare at different sites 
in <21 days post 
anakinra
Unknown
10 1 course 
(100 mg/d × 5 days)
Poor None No repeat flare within 
21 days
CHF 
decompensation
11 2 courses 
(100 mg/d × 3 days)
Substantial None No repeat flare within 
21 days
Unknown
12 1 course 
(100 mg/d × 14 days)
Substantial Injection site 
reaction
No repeat flare within 
21 days
CHF 
decompensation
13 1 course 
(100 mg/d × 5 days)
Excellent None No repeat flare within 
21 days
Unknown
Abbreviations: CHF, congestive heart failure; N/A, not applicable.
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diuretic use, of death during the observation period (Figure 2). 
Increased mortality with antecedent anakinra prescription for 
acute gout essentially was linked strongly to comorbidities 
(Figure 2).
Discussion
Our study highlights that one of the strongest predictors of 
anakinra use for gout flare treatment is that other options are 
constrained by comorbidities. Patients requiring anakinra also 
were more likely to have greater serum urate elevation and 
tophaceous disease at baseline visit, East Asian descent, and, at 
the end of the observation period, higher mortality. Bevis et al21 
identified 4 clusters in a cross section of gout comorbidity clus-
tering: C1 (elderly with frequent gout attacks; 97% with CKD), 
C2 (isolated gout and frequent alcohol intake), C3 (hyperten-
sion, diabetes, hyperlipidemia, coronary heart disease, and/or 
CKD were most prevalent and this group had the highest fre-
quency prescription of ULT), and C4 (obese and with hyper-
tension). Here, anakinra recipients appeared to fall under 
cluster 3, with associated ULT and statin use. Gout is associ-
ated with premature mortality.22 Here, the death signal on fac-
tor analysis was tightly linked to insulin and loop diuretic use, 
thereby implicating comorbid diseases. Patients with more 
comorbidities, especially atherosclerosis, could have elevated 
systemic inflammation, potentially predisposing to more severe 
attacks of gout. Cardiovascular disease is more prevalent in 
gout than controls.23 Here, 22% of all patients had CHF and 
81% had hypertension. East Asians (particularly Pacific 
Islanders) were disproportionately represented in anakinra 
recipients, but confounders and bias as well as low subject 
numbers may have contributed to this observation. Larger-
scale studies would be indicated to identify and validate any 
potential genetic predisposition, such as by ABCG2 variant 
Q141K,23 to higher inflammatory state and comorbidities in 
gout.24
Limitations of this study include that case-control studies 
have high susceptibility to bias, but performing the study in 
the same VA group was an effort to reduce such issues. A rela-
tively complex VA patient population with prevalent comor-
bidities was examined, which, as in other VA-based studies, 
imposes contraindications to the use of NSAIDs, colchicine, 
or corticosteroids.3 Additional limitations included exclusively 
retrospective analyses, small sample size, men only receiving 
anakinra, and quite high prevalence of minority ethnic and 
racial groups.
In summary, the patient profile for anakinra prescription 
for acute gout was associated with specific characteristics at 
baseline rheumatology visit. These included uncontrolled 
hyperuricemia and a high body urate burden (reflected by pal-
pable tophi), as well as East Asian descent, and a significantly 
increased number of comorbidities that could heighten sys-
temic inflammation and predispose to continuing sympto-
matic gout. The increased all-cause mortality signal in this 
study, associated with prior use of anakinra for acute gout flare, 
was linked to higher comorbidity burden, especially cardiovas-
cular disease.
Author Contributions
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Figure 2. Contribution of categorical variables to the first and second dimensions of a factor analysis of mixed data. Categories of the categorical data 
groups are labeled on the plot regarding their contribution to the first dimension (x-axis) and the second distinct grouping of death with either insulin or 
loop diuretic use. Dim 1 indicates dimension 1 representing 24% of the variance of the analyzed variables; NSAIDs, nonsteroidal anti-inflammatory drugs; 
ULT, urate-lowering therapy; Dim2, dimension 2 representing 11.8% of the variance of the analyzed variables.
Sharma et al 5
Data Sharing
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